Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in Schizophrenia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 77, Issue 2, 2007, Pages 79-85

  Smesny, Stefan ^a   Klemm, Silke ^a   Stockebrand, Margit ^a   Grunwald, Sebastian ^a   Gerhard, Uwe Jens ^a   Rosburg, Timm ^a,b   Sauer, Heinrich ^a   Blanz, Bernhard ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NICOTINIC ACID; OLANZAPINE; PROSTAGLANDIN; QUETIAPINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLUSHING; HERITABILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; MALE; MEDICAL ASSESSMENT; NICOTINIC ACID DEFICIENCY; OPTICAL REFLECTION SPECTROSCOPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RELATIVE; SCHIZOPHRENIA; SCHOOL CHILD; SPECTROSCOPY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; FLUSHING; HUMANS; MICROSCOPY, INTERFERENCE; NIACIN; PHENOTYPE; PROSTAGLANDINS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN TESTS; SMOKING; VASODILATOR AGENTS;

EID: 35148838208     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2007.08.006     Document Type: Article

References (37)

1. Smesny S., Rosburg T., Riemann S., and Sauer H. Altered prostaglandin mediated skin flush in schizophrenia-implications for early psychosis interventions. In: Szuhaj B.F., and van Nieuwenhuyzen W. (Eds). Nutrition and Biochemistry of Phospholipids (2003), AOCS Press, Champaign, IL 50-60
2. Benyo Z., Gille A., Bennett C.L., Clausen B.E., and Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharmacol. 70 (2006) 1844-1849
3. Maciejewski-Lenoir D., Richman J.G., Hakak Y., Gaidarov I., Behan D.P., et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol. 126 (2006) 2637-2646
4. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci. 27 (2006) 384-390
5. Maclean R., Ward D.S., Glen I., Roberts S.J., and Ross B.M. On the relationship between methylnicotinate-induced skin fush and fatty acid levels in acute psychosis. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 27 (2003) 927-933
6. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., et al. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot. Essent. Fatty Acids 55 (1996) 9-15
7. Gottesman I.I., and Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiat. 160 (2003) 636-645
8. Smesny S., Berger G., Rosburg T., Riemann S., Riehemann S., et al. Potential use of the topical niacin skin test in early psychosis-a combined approach using optical reflection spectroscopy and a descriptive rating scale. J. Psychiat. Res. 37 (2003) 237-247
9. Smesny S., Rosburg T., Riemann S., Baur K., Rudolph N., et al. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 72 (2005) 393-402
10. Wittchen H.-U., Fydrich T., and Zaudig M. Strukturiertes Klinisches Interview für DSM-IV (1997), Göttingen Hogrefe Verlag
11. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (1983), The University of Iowa, Iowa
12. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (1984), The University of Iowa, Iowa
13. Smesny S., Riemann S., Riehemann S., and Bellemann M.E.H.S. Quantitative assessment of niacin induced skin flusing using optical reflection spectroscopy-method and clinical application. Biomed. Tech. 46 (2001) 280-286
14. Gershon E.S., and Goldin L.R. Clinical methods in psychiatric genetics, I: robustness of genetic marker investigative strategies. Acta Psychiat. Scand. 74 (1986) 113-118
15. Messamore E., Hoffman W.F., and Janowsky A. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophrenia Res. 62 (2003) 251-258
16. Puri B.K., Easton T., Das I., Kidane L., and Richardson A.J. The niacin skin flush test in schizophrenia: a replication study. Int. J. Clin. Pract. 55 (2001) 368-370
17. Puri B.K., Hirsch D., Easton T., and Richardson A.D. A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiat. 26 (2002) 49-52
18. Ross B.M., Hughes H.B., Turenne S., Seeman M., and Warsh J. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. Eur. Neuropsychopharmacol. 14 (2004) 191-197
19. Rybakowski J., and Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiat. 29 (1991) 834-836
20. Shah S.H., Vankar G.K., Peet M., and Ramchand C.N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophrenia Res. 43 (2000) 163-164
21. Ward P.E., Sutherland J., Glen E.M., and Glen A.I. Niacin skin flush in schizophrenia: a preliminary report. Schizophrenia Res. 29 (1998) 269-274
22. Hudson C.J., Lin A., Cogan S., Cashman F., and Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiat. 41 (1997) 507-513
23. Lin S.H., Liu C.M., Chang S.S., Hwu H.G., Liu S.K., et al. Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophrenia Bull. 33 (2007) 174-182
24. Waldo M.C. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophrenia Res. 40 (1999) 49-53
25. Nikolov I., Poriazova N., Milev R., Toncheva D., and Kirov G. Niacin flush skin test in parent-offspring trios affected with schizophrenia. Am. J. Med. Genet. 114 (2002)
26. Shah S.H., Ramchand C.N., and Peet M. The niacin skin flush test: first-degree relatives show responses intermediate between patients and controls. Schizophrenia Res. 36 (1999) 314
27. Ross M.A. Could oxidative stress be a factor in neurodevelopmental disorders?. Prostaglandins Leukot. Essent. Fatty Acids 63 (2000) 61-63
28. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiat. 53 (2003) 56-64
29. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Res. 58 (2002) 1-10
30. Reddy R., Keshavan M., and Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophrenia Res. 62 (2003) 205-212
31. Reddy R.D., Keshavan M.S., and Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophrenia Bull. 30 (2004) 901-911
32. Marchbanks R.M., Ryan M., Day I.N., Owen M., McGuffin P., et al. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophrenia Res. 65 (2003) 33-38
33. Tosic M., Ott J., Barral S., Bovet P., Deppen P., et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 79 (2006) 586-592
34. Muller N. Immunological and infectious aspects of schizophrenia. Eur. Arch. Psychiat. Clin. Neurosci. 254 (2004) 1-3
35. Horrobin D.F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1 (1977) 936-937
36. Müller N., Riedel M., Ackenheil M., and Schwarz M.J. The role of immune function in schizophrenia: an overview. Eur. Arch. Psychiat. Clin. Neurosci. 249 Suppl. 4 IV (1999) 62-68
37. Smesny S, Rosburg T, Baur K, Rudolph N, Sauer H. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychopharmacology 2007, in press.